Recently,two groups identified low-density lipoprotein receptorrelated protein 8(LRP8)as a functional entry receptor for tickborne encephalitis virus(TBEV)in Nature1 and PNAS2 respectively.These two studies shed cruci...Recently,two groups identified low-density lipoprotein receptorrelated protein 8(LRP8)as a functional entry receptor for tickborne encephalitis virus(TBEV)in Nature1 and PNAS2 respectively.These two studies shed crucial light on the role of LRP8 in the neuropathogenesis of TBEV and lay a solid foundation for the development of LRP8-targeted antiviral therapeutics and vaccines.Tick-borne encephalitis virus(TBEV)is a clinically significant orthoflavivirus transmitted to humans predominantly via the bite of infected ticks.It targets the central nervous system(CNS),leading to neurological complications and potentially fatal outcomes in severe cases across Europe and Asia.3 With the expansion of TBE-endemic areas,vaccines are available,but no specific antiviral drugs exist for TBEV infection,highlighting the urgent need for in-depth research into TBEV pathogenic mechanisms and the development of effective preventive and therapeutic strategies.4 TBEV entry into host cells relies on host factors,particularly cellular receptors,which have not been definitively identified before,hindering the advancement of antiviral strategies.展开更多
基金supported by the Innovation Program of the Chinese Academy of Agricultural Sciences(No.CAASCSLPDCP-202403)the Agricultural Science and Technology Innovation Program(ASTIP)(No.ASTIP-IAS-15)the Central Public-interest Scientific Institution Basal Research Fund(No.2023-YWF-ZYSQ-09).
文摘Recently,two groups identified low-density lipoprotein receptorrelated protein 8(LRP8)as a functional entry receptor for tickborne encephalitis virus(TBEV)in Nature1 and PNAS2 respectively.These two studies shed crucial light on the role of LRP8 in the neuropathogenesis of TBEV and lay a solid foundation for the development of LRP8-targeted antiviral therapeutics and vaccines.Tick-borne encephalitis virus(TBEV)is a clinically significant orthoflavivirus transmitted to humans predominantly via the bite of infected ticks.It targets the central nervous system(CNS),leading to neurological complications and potentially fatal outcomes in severe cases across Europe and Asia.3 With the expansion of TBE-endemic areas,vaccines are available,but no specific antiviral drugs exist for TBEV infection,highlighting the urgent need for in-depth research into TBEV pathogenic mechanisms and the development of effective preventive and therapeutic strategies.4 TBEV entry into host cells relies on host factors,particularly cellular receptors,which have not been definitively identified before,hindering the advancement of antiviral strategies.
